Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Photodynamic Therapy (PDT) in Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00984243
First received: December 24, 2007
Last updated: November 13, 2012
Last verified: November 2012

December 24, 2007
November 13, 2012
February 1994
October 2006   (final data collection date for primary outcome measure)
Evaluate the impact of PDT on these patients by determining the percentage of patients who are spared surgery. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00984243 on ClinicalTrials.gov Archive Site
  • Morbidity,overall mortality and lung cancer mortality. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Rate of subsequent lung cancer. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Relative cost of PDT and surgery. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Change in pulmonary function over time. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Effect on quality of life. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Patient preferences for PDT and surgery. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.

This study is being done to determine whether a substance called hematoporphyrin can be used to treat tumors in various locations in the body when used in association with a laser. Hematoporphyrin is a substance that is taken up by cancerous cells. When these cells are exposed to the energy emitted by a laser source, chemical reactions occur in the cell and cause the cells to die. It is hoped that this treatment method may be able to selectively destroy malignant cells without damaging surrounding healthy tissue.

Lung cancer is currently the leading cause of death in both women and men in the United States and continues to be a major problem in several other countries in the world. Detection, localization, and surgical treatment at an early stage, provides the best opportunity for long-term survival for patients with non-sma11 cell lung cancer at this time. Studies examining the utility of screening patients at high risk for lung cancer with sputum cytology and chest roentgenograms showed that, despite a higher frequency of detecting and resecting early cancers in the screened group, there was no difference between the screened group and the control group in overall cancer mortality.

The purpose of this study is to determine if photodynamic therapy (PDT) is an alternative to surgical resection in patients with early stage) roentgenographically occult squamous cell carcinoma of the lung who are candidates for surgery. If PDT is successful, it would remove the indication for surgery and eliminate the need for an operation. The specific goals are to evaluate the impact of PDT on these patients by determining the percentage of patients who are spared surgery as wel1 as the following: morbidity, overall mortality, lung cancer mortality, the rate of subsequent lung cancer, the relative cost of PDT and surgery, the change in pulmonary function over time, the effect on quality of life, and the patient preferences for PDT and surgery.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Lung Cancer
Procedure: PHOTODYNAMIC THERAPY (PDT)

Photodynamic Procedure:

Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.

It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.

Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens

Energy density:

Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2

Experimental: Photodynamic Therapy
PHOTODYNAMIC THERAPY (PDT)
Intervention: Procedure: PHOTODYNAMIC THERAPY (PDT)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
October 2006
October 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient less than 75 years of age.
  • Squamous cell lung cancer proven by biopsy or repeated Brushings obtained from the same location at separate bronchoscopies.
  • Occult lung cancer by chest roentgenogram and CT scan If CT scan is abnormal, mediastinoscopy is negative.
  • Cancer is bronchoscopically superficial as defined in section IV, E.
  • Estimated size less than 1 cm diameter on the surface of the bronchus with the surface area of 0.7 to 1.0 cm2.
  • Location in the trachea, main stem bronChi, lobar bronchi, segmental bronchi, or subsegmental bronchi.
  • Medical condition permits surgery: cardiovascular status is satisfactory for operation and postoperative FEVl is predicted to be greater than 0.75 liter.
  • Patients will complete quality of life questionnaire and a spirometry which will include forced expiratory volume in 1 second (FEVl) and forced vital capacity (FVC).
  • On bronchoscopic biopsy, the carcinoma is entirely in situ or shows no more than 2 mm of microinvasion.
  • The characteristics of the mucosa. may include paleness, opacity, loss of luster, roughness, micro-granularity.
  • The mucosal folds may demonstrate lack of clarity. thickening, disappearance.
  • There may be small nodular protrusion of tumor into the lumen
  • The peripheral extent of tumor invasion can be confirmed endoscopically.

Exclusion Criteria:

  • A medical disease which excludes surgery as an option
  • A postoperative FEVl predicted to be less than 0.75 liter
  • A previous carcinoma or other malignancy not curatively treated
  • The presence of simultaneous lung cancers
  • CT scan of the chest shows thickening of the bronchial wall or extension beyond the bronchial wall in the area of the cancer
Both
50 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00984243
281-92, PulmMed 649
No
Eric S. Edell, M.D., Mayo Clinic
Mayo Clinic
Not Provided
Principal Investigator: Eric S. Edell, M.D. Mayo Clinic
Mayo Clinic
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP